Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of piRNAs as prognostic markers in diffuse large B-cell lymphoma

A diffuse, B-cell technology, applied in the field of life sciences, which can solve the problems of inability to predict the prognosis of patients and ignoring the heterogeneity of molecular biology.

Active Publication Date: 2020-12-04
SUZHOU UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it still needs to be pointed out that the IPI index only includes some clinical indicators, but ignores the heterogeneity of molecular biology reflecting DLBCL, so the IPI index still cannot accurately and effectively predict the prognosis of a considerable number of patients

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of piRNAs as prognostic markers in diffuse large B-cell lymphoma
  • Use of piRNAs as prognostic markers in diffuse large B-cell lymphoma
  • Use of piRNAs as prognostic markers in diffuse large B-cell lymphoma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024] The application of piRNA in the treatment of diffuse large B-cell lymphoma, the piRNA is used as a marker for the prognosis of diffuse large B-cell lymphoma, and the type of piRNA is piRNA-42435 or piRNA-30374.

[0025] The verification method of the present invention detects the differential expression of piRNAs in paraffin-embedded tissues of 6 DLBCL patients by microarray, and finds that the expression levels of piRNA-42435, piRNA-30374 and piRNA30222 in DLBCL cases with poor prognosis are significantly higher than those in DLBCL with good prognosis Therefore, it can be speculated that the expression levels of piRNA-42435, piRNA-30374 and piRNA30222 are related to the prognosis of DLBCL patients.

[0026] In order to further prove the above conjecture, the verification method of the present invention detected the expression levels of piRNA-42435, piRNA-30374 and piRNA30222 in paraffin-embedded tissues of 42 cases of DLBCL patients. The patients were divided into two ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of piRNA to serving as a prognostic marker for diffuse large B cell lymphoma, wherein the specific type of piRNA is piRNA-42435 and piRNA-30374. The prognosis evaluation of a patient subjected to the diffuse large B cell lymphoma is conducted by detecting the expression levels of piRNA-42435 and piRNA-30374 of the patient, the unfavorable prognosis case is screened at the early stage, and the application helps to select the clinical treatment plan and improve the prognosis.

Description

technical field [0001] The invention belongs to the field of life sciences, and relates to the application of piRNA in the treatment of diffuse large B-cell lymphoma, specifically, the application of piRNA as a prognostic marker in diffuse large B-cell lymphoma in B-cell lymphoma. Background technique [0002] Diffuse large B-cell lymphoma (DLBCL) is a malignant lymphoma of B-cell origin, aggressive clinical manifestations, and requires high-efficiency chemotherapy. It is also the most common non-Hodgkin lymphoma Lymphoma (Non Hodgkin's lymphoma, NHL) accounts for about 40% of NHL. The cause of the disease is not yet clear, and the incidence rate is increasing year by year, and the occurrence of DLBCL is not limited by age. Clinically, it is most common in middle-aged and elderly patients, and the median age of onset is 70 years old. In Western countries, the incidence of DLBCL accounts for about 31% of the incidence of NHL, and the incidence of DLBCL in Asian countries is...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C12Q1/6886
CPCC12Q1/6886C12Q2600/118C12Q2600/158C12Q2600/178
Inventor 李炳宗庄文卓
Owner SUZHOU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com